The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 13, Issue 12, 2012, Pages 1175-1184

  Zhang, Bo ^a   Shan, Hong ^a   Li, Dan ^a   Li, Zheng Ran ^a   Zhu, Kang Shun ^a   Jiang, Zai Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bioluminescence imaging; Cisplatin; Hepatocellular carcinoma; Lentiviral; Mesenchymal stem cells; Synergistic effect; TRAIL

Indexed keywords

CISPLATIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE VECTOR; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867120056     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21347     Document Type: Article

References (59)

1. Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2005; 10:269-81; PMID:15821247; http://dx.doi.org/10.1634/theoncologist.10-4- 269.
2. Roberts LR. Sorafenib in liver cancer - just the beginning. N Engl J Med 2008; 359:420-2; PMID:18650519; http://dx.doi.org/10.1056/NEJMe0802241.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48:2047-63; PMID:19003900; http://dx.doi.org/10.1002/hep.22580.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34; PMID:19095497; http://dx.doi.org/10.1016/S1470-2045(08)70285-7.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/ NEJMoa0708857.
6. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263:590-9; PMID:22438359; http://dx.doi.org/ 10.1148/radiol.12111550.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10. 1016/1074-7613(95)90057-8.
8. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7:1362-9; PMID:11350907.
9. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8:808-15; PMID:12118245.
10. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis- inducing ligand and CPT-11. Cancer Res 2003; 63:4713-23; PMID:12907654.
11. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62:5800-6; PMID:12384541.
12. Zhang B, Shan H, Li D, Li ZR, Zhu KS, Jiang ZB, et al. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5. Oncol Rep 2011; 25:461-8; PMID:21152876.
13. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009; 284:11121-33; PMID:19261616; http://dx.doi.org/10.1074/jbc.M806268200.
14. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16:5189-99; PMID:20884624; http://dx.doi.org/10.1158/1078-0432.CCR-09-3389.
15. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007; 67:9490-500; PMID:17909059; http://dx.doi.org/10.1158/0008-5472.CAN-07-0598.
16. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000; 32:482-90; PMID:10960439; http://dx.doi.org/10.1053/jhep.2000.16266.
17. Xu ZW, Kleeff J, Friess H, Büchler MW, Solioz M. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 2003; 23(1A):251-8; PMID:12680221.
18. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway. Mol Cancer Ther 2011; 10:198-208; PMID:21220502; http://dx.doi.org/10. 1158/1535-7163.MCT-10-0725.
19. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 2011; 29:511-20; PMID:21877938; http://dx.doi.org/10.3109/07357907.2011.605412.
20. Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y, et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer 2011; 11:54; PMID:21291526; http://dx.doi.org/10.1186/1471-2407-11-54.
21. Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, et al. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiationinduced bystander signaling in lung adenocarcinoma. Cancer Res 2007; 67:11811-20; PMID:18089811; http://dx.doi.org/10.1158/0008-5472.CAN-07-0722.
22. Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, Zhao QL, et al. Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. J Orthop Res 2010; 28:739-45; PMID:20041491.
23. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/TRAIL in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8; PMID:11561060.
24. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333-9; PMID:15251125; http://dx.doi.org/10.1016/j.coph.2004.02.006.
25. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008; 30:121-7; PMID:18249090; http://dx.doi.org/10.1016/j.jaut.2007.12.008.
26. Eliopoulos N, Francois M, Boivin MN, Martineau D, Galipeau J. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 2008; 68:4810-8; PMID:18559528; http://dx.doi.org/10.1158/0008-5472.CAN-08-0160.
27. Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 2009; 115:13-22; PMID:19051291; http://dx.doi.org/10. 1002/cncr.24013.
28. Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L, et al. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 2010; 29:2784-94; PMID:20190814; http://dx.doi.org/10.1038/onc.2010.38.
29. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010; 70:3718-29; PMID:20388793; http://dx.doi.org/10.1158/0008-5472.CAN-09- 1865.
30. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69:4134-42; PMID:19435900; http://dx.doi.org/10.1158/0008-5472.CAN-08-4698.
31. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008; 12(6B):2628-43; PMID:18373740; http://dx.doi.org/10.1111/j.1582-4934.2008.00317.x.
32. Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol 2011; 13:61-9; PMID:21062796; http://dx.doi.org/10.1093/neuonc/noq147.
33. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68:9614-23; PMID:19047138; http://dx.doi.org/10.1158/0008-5472.CAN-08-0451.
34. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307-18; PMID:15833864.
35. Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009; 27:2320-30; PMID:19544410; http://dx.doi.org/10.1002/stem.136.
36. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9; PMID:3537791.
37. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010; 12:615-25; PMID:20230221; http://dx.doi.org/10.3109/ 14653241003631815.
38. Dwyer RM, Khan S, Barry FP, O'Brien T, Kerin MJ. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010; 1:25; PMID:20699014; http://dx.doi.org/10.1186/scrt25.
39. Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009; 75:843-53; PMID:18849123; http://dx.doi.org/10.1016/j.ijrobp.2008.06.1953.
40. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 2008; 26:2955-63; PMID:18772312; http://dx.doi.org/10.1634/stemcells.2008-0512.
41. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009; 11:373-81; PMID:19274675; http://dx.doi.org/10. 1002/jgm.1313.
42. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009; 109:259-302; PMID:19053809; http://dx.doi.org/10.1021/cr800409e.
43. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-40; PMID:18852116; http://dx.doi.org/10.1158/1535-7163.MCT-08-0013.
44. Nishihira S, Okubo N, Takahashi N, Ishisaki A, Sugiyama Y, Chosa N. High-cell density-induced VCAM1 expression inhibits the migratory ability of mesenchymal stem cells. Cell Biol Int 2011; 35:475-81; PMID:21073443; http://dx.doi.org/10.1042/CBI20100372.
45. Ishii K, Yoshida Y, Akechi Y, Sakabe T, Nishio R, Ikeda R, et al. Hepatic differentiation of human bone marrow- derived mesenchymal stem cells by tetracycline-regulated hepatocyte nuclear factor 3beta. Hepatology 2008; 48:597-606; PMID:18666263; http://dx.doi.org/10.1002/hep.22362.
46. Shimomura T, Yoshida Y, Sakabe T, Ishii K, Gonda K, Murai R, et al. Hepatic differentiation of human bone marrow-derived UE7T-13 cells: Effects of cytokines and CCN family gene expression. Hepatol Res 2007; 37:1068-79; PMID:17627621; http://dx.doi.org/10.1111/j.1872-034X.2007.00162.x.
47. Mori T, Kiyono T, Imabayashi H, Takeda Y, Tsuchiya K, Miyoshi S, et al. Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol 2005; 25:5183-95; PMID:15923633; http://dx.doi.org/10.1128/MCB.25.12.5183-5195.2005.
48. You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54:879-89; PMID:21618573; http://dx.doi.org/10.1002/hep.24450.
49. Van Damme A, Thorrez L, Ma L, Vandenburgh H, Eyckmans J, Dell'Accio F, et al. Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells 2006; 24:896-907; PMID:16339997; http://dx.doi.org/10.1634/stemcells.2003-0106.
50. Miyoshi N, Oubrahim H, Chock PB, Stadtman ER. Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Natl Acad Sci U S A 2006; 103:1727-31; PMID:16443681; http://dx.doi.org/10.1073/ pnas.0510346103.
51. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5:39-47; PMID:16319528; http://dx.doi.org/10.4161/cbt.5.1.2236.
52. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43:134-43; PMID:16374840; http://dx.doi.org/10.1002/hep.20994.
53. Hsieh JL, Wu CL, Lee CH, Shiau AL. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res 2003; 9:338-45; PMID:12538486.
54. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006; 12:4306-14; PMID:16857806; http://dx.doi.org/10.1158/1078-0432.CCR-05- 2568.
55. Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, et al. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med 2007; 48:2011-20; PMID:18006616; http://dx.doi.org/10.2967/jnumed.107.043166.
56. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009; 27:2614-23; PMID:19650040; http://dx.doi.org/10.1002/stem.187.
57. Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010; 14:2292-304; PMID:19508388; http://dx.doi.org/10.1111/j.1582-4934. 2009.00794.x.
58. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77:858-63; PMID:8608475; http://dx.doi.org/10.1002/ (SICI)1097-0142(19960301)77:5〈858::AIDCNCR8〉 3.0.CO;2-A.
59. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004; 25:443-8; PMID:15019676; http://dx.doi.org/10.1016/j.ejcts.2003.11.031.